ha14-1 has been researched along with Diffuse Large B-Cell Lymphoma in 3 studies
ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate: a BH3 mimetic; synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akl, H | 1 |
| La Rovere, RM | 1 |
| Janssens, A | 1 |
| Vandenberghe, P | 1 |
| Parys, JB | 1 |
| Bultynck, G | 1 |
| Dasmahapatra, G | 1 |
| Lembersky, D | 1 |
| Rahmani, M | 1 |
| Kramer, L | 1 |
| Friedberg, J | 1 |
| Fisher, RI | 1 |
| Dent, P | 1 |
| Grant, S | 1 |
| Hertan, LM | 1 |
| Koumenis, C | 1 |
3 other studies available for ha14-1 and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
HA14-1 potentiates apoptosis in B-cell cancer cells sensitive to a peptide disrupting IP 3 receptor / Bcl-2 complexes.
Topics: Apoptosis; B-Lymphocytes; Benzopyrans; Cell Line, Tumor; Endoplasmic Reticulum; Humans; Inositol 1,4 | 2015 |
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Cell Line, T | 2009 |
Piling up the JNK: drug synergy through ER stress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Boronic Acids; Bortezomib; Drug Synergi | 2009 |